Race challenges big pharma mindset – Australia News

0
19

For many cancer sufferers, the side effects of traditional chemotherapy treatments can compound an already difficult situation.

Perth-based Race Oncology is hoping Bisantrene, which it believes to be a ‘cleaner chemotherapy’, will deliver on its potential to treat a range of cancers.

Bisantrene was developed in the 1980s by a US pharmaceutical company, but fell between the cracks at pharmaceutical multinationals, after a series of mergers, largely for financial reasons.

To read more, please Login or Register below

Sign up here for free access to 7 articles per month + twice daily business email alerts.

Problems, questions, feedback? Please call +61 8 9288 2100

click here to read the rest of this story

LEAVE A REPLY

Please enter your comment!
Please enter your name here